All In Biotech

Drug Trial Radar · NCT04764396

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Mar 12, 2021

Primary completion

Apr 6, 2021

Study completion Jul 6, 2021

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.

Conditions

  • Pancreas
  • Mass Lesion

Interventions

  • Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)Combination product

    The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.

  • SalineDrug

    FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cellularity Captured in Fine Needle Biopsies for the Heparin GroupTime frame: Day 1 (biopsy tissue obtained)
  2. Blood Contamination in Fine Needle Biopsies for the Heparin GroupTime frame: Day 1 (biopsy tissue obtained)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.